全身用外源性孕激素联合或不联合雌激素与静脉曲张静脉手术率降低相关
基于TriNetX数据库的大型人群队列研究,比较无激素使用对照、单用孕激素及雌孕激素联合治疗三组静脉曲张患者的静脉手术率。倾向匹配后,两种激素方案均与静脉手术率显著降低相关,单用孕激素组手术最少;作者认为需进一步研究孕激素在静脉曲张进展中的作用及辅助治疗价值。
要点
- 倾向匹配后,雌孕激素联合组任何静脉手术风险低于对照(RR 0.68,95%CI 0.61-0.76,P<.001)。
- 单用孕激素组任何静脉手术风险低于对照(RR 0.57,95%CI 0.52-0.62,P<.001)。
- 与单用孕激素组相比,雌孕激素联合组总体静脉手术率更高(RR 1.16,95%CI 1.00-1.34,P=.048)。
核心结论
- 尽管雌孕激素联合与单用孕激素治疗的深静脉血栓和妊娠风险不同,两种全身激素方案均与静脉曲张静脉手术显著少于对照相关,单用孕激素组手术最少。
- 作者认为需进一步研究全身孕激素在静脉曲张疾病进展中的作用及作为辅助治疗的效用。
研究设计与样本
- 基于TriNetX数据库的人群队列研究,纳入国际疾病分类第10版诊断为无症状静脉曲张、慢性静脉功能不全和复杂性静脉曲张(炎症或溃疡)的患者。
- 匹配前对照674838例、雌孕激素联合7597例、单用孕激素13758例;按年龄、种族、既往妊娠和体重指数等已知及理论风险因素进行1:1倾向匹配。
- 按静脉曲张症状状态和绝经前状态(年龄<40岁)进一步分层分析。
主要发现
- 与对照相比,雌孕激素联合组接受stab phlebectomy较少(RR 0.52,95%CI 0.42-0.64,P<.001)、腔内消融较少(RR 0.50,95%CI 0.43-0.59,P<.001)或任何静脉干预较少(RR 0.68,95%CI 0.61-0.76,P<.001),硬化治疗无差异(P=.12)。
- 与对照相比,单用孕激素组接受stab phlebectomy较少(RR 0.37,95%CI 0.31-0.43,P<.001)、腔内消融较少(RR 0.35,95%CI 0.31-0.40,P<.001)、硬化治疗较少(RR 0.65,95%CI 0.56-0.75,P<.001)及任何静脉手术较少(RR 0.57,95%CI 0.52-0.62,P<.001)。
- 与单用孕激素组相比,雌孕激素联合组硬化治疗率更高(RR 1.38,95%CI 1.12-1.72,P=.003)且总体静脉手术率更高(RR 1.16,95%CI 1.00-1.34,P=.048)。
- 按症状状态和绝经状态分层分析显示亚组结果相似。
- 雌孕激素联合组在观察前1200天妊娠风险低于对照,但随后妊娠风险更高(RR 1.38,95%CI 1.21-1.57,P<.001);Kaplan-Meier分析显示整个观察期静脉干预率较低。
局限性
- 作者结论指出需进一步研究全身孕激素在静脉曲张疾病进展中的作用及作为辅助治疗的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Risk factors for varicose veins (VVs) such as female sex, pregnancy, and obesity are high estrogen states, yet the role of systemic progestins with or without estrogens (SPEs) in VV management is not well characterized. This study investigates how SPE use affects rates of venous procedures for patients with VV. METHODS: The TriNetX database was queried for subjects with International Classification of Diseases, 10th edition, diagnoses of asymptomatic VV, chronic venous insufficiency, and complicated VV (inflammation or ulceration). Patients were divided into a control cohort with no subsequent SPE use, a progestin-only cohort, and a combined estrogen-progestin (CEP) cohort. Further stratification by VV symptomology and premenopausal status (age <40 years) was also performed. Cohorts were one:one propensity matched on known and theorized risk factors for VV including age, race, prior pregnancy, and body mass index. The outcomes of interest were deep vein thrombosis, pregnancy, stab phlebectomy, endovenous ablation, and sclerotherapy. RESULTS: Database query yielded 674,838 controls, 7597 CEP patients, and 13,758 progestin-only patients before matching. After propensity matching, compared with controls, the CEP cohort received fewer stab phlebectomies (relative risk [RR], 0.52; 95% confidence interval [CI], 0.42-0.64; P < .001), endovenous ablations (RR, 0.50; 95% CI, 0.43-0.59; P < .001) or any venous interventions (RR, 0.68; 95% CI, 0.61-0.76; P < .001), with no difference in sclerotherapy (P = .12). Similarly, the progestin-only cohort was less likely to receive stab phlebectomy (RR, 0.37; 95% CI, 0.31-0.43; P < .001), endovenous ablation (RR, 0.35; 95% CI, 0.31-0.40; P < .001), sclerotherapy (RR, 0.65; 95% CI, 0.56-0.75; P < .001), and any venous procedure (RR, 0.57; 95% CI, 0.52-0.62; P < .001). Compared with the progestin-only cohort, the CEP cohort had higher rates of sclerotherapy (RR, 1.38; 95% CI, 1.12-1.72; P = .003) and overall venous procedures (RR, 1.16; 95% CI, 1.00-1.34; P = .048). When possible, analysis stratified by symptomatic status and menopausal status revealed similar findings for subcohorts. Finally, the CEP cohort had lower risk of pregnancy than controls during the first 1200 days of observation, but subsequently had greater risk of pregnancy (RR, 1.38; 95% CI, 1.21-1.57; P < .001). Kaplan-Meier analysis showed that the rates of venous intervention were lower throughout the observation period. CONCLUSIONS: This large, population-based cohort study demonstrated that, despite variable risk of deep vein thrombosis and pregnancy for estrogen-progestin and progestin-only treatment cohorts, both SPE formulations were associated with significantly fewer venous procedures for VVs than controls, with progestin-only cohorts undergoing the fewest procedures. This warrants further investigation into the role of SPE in VV disease progression and the utility of systemic progestins as an adjunct therapy for VVs.
引用
- Jain P, Ostrovsky A, DiMuzio P, et al. Systemic exogenous progestins with or without estrogens are associated with decreased rates of venous procedures for varicose veins. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 40120674. doi:10.1016/j.jvsv.2025.102235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。